Article
Oncology
Osama E. Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew S. Brohl, Philippe L. Bedard, Daniel J. Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, Michael Manos, Mariano Severgnini, Scott Rodig, F. Stephen Hodi
Summary: This study investigated the efficacy and safety of the combination of ziv-aflibercept and pembrolizumab in patients with advanced solid tumors. The results showed that this combination therapy had antitumor activity and an acceptable safety profile in solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Tae Hwan Moon, Gwon Hui Jo, Eoi Jong Seo, Kyung Tae Kim, Eu Jeong Ku, Soon Kil Kwon, Jin Young Kim, Ju Byung Chae, Dong Yoon Kim
Summary: This study aimed to investigate the association between response to intravitreal bevacizumab injection and renal function in DME patients. The results showed that BCVA and CST significantly improved after consecutive IVBIs in patients with preserved renal function. For patients with decreased renal function, switching to aflibercept or dexamethasone implant resulted in better treatment outcomes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Erik van Dijk, Erik van Werkhoven, Rebecca Asher, Jennifer K. Mooi, David Espinoza, Hendrik F. van Essen, Harm van Tinteren, Nicole C. T. van Grieken, Cornelis J. A. Punt, Niall C. Tebbutt, Bauke Ylstra
Summary: The VEGF-A monoclonal antibody bevacizumab is recommended as first-line treatment for metastatic colorectal cancer patients. A retrospective study showed improved survival outcomes in patients with chromosome 18q11.2-q12.1 loss who received bevacizumab treatment. The analysis of the AGITG-MAX trial also provided supportive evidence for chromosome 18q11.2-q12.1 as a predictive marker for bevacizumab in mCRC patients.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Ophthalmology
Emer Chang, Amandeep S. Josan, Ravi Purohit, Chetan K. Patel, Kanmin Xue
Summary: This study compared bevacizumab, ranibizumab, aflibercept, and laser treatment as primary therapies for retinopathy of prematurity (ROP) in terms of retreatment rate. The results showed that laser treatment had a higher success rate than ranibizumab in type 1 ROP, while bevacizumab had a higher success rate than laser treatment in Zone I ROP. Aflibercept and bevacizumab had a longer duration of action compared to ranibizumab for ROP.
Article
Chemistry, Medicinal
Amirfarbod Yazdanyar, Charles L. Cai, Jacob V. Aranda, Eric Shrier, Kay D. Beharry
Summary: This study found that Eylea is not as effective as Avastin in promoting angiogenesis, although the lower dose of Eylea may be more effective than the higher dose. Additionally, Eylea may promote normal vascular development by regulating the expression of factors such as VEGFR-1 and Notch/Jagged-1.
Review
Biochemistry & Molecular Biology
Ji Won Han, Jeong Won Jang
Summary: Atezolizumab in combination with bevacizumab (AB) is the first treatment to show superiority over sorafenib and is now the preferred systemic treatment for HCC patients in stage C. However, a significant number of patients do not achieve survival or significant responses, highlighting the need for predictive biomarkers. This review summarizes current data from experimental and clinical studies, providing valuable information for clinicians and researchers in clinical practice and study design.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Alessandro Ottaiano, Stefania Scala, Mariachiara Santorsola, Anna Maria Trotta, Crescenzo D'Alterio, Luigi Portella, Ottavia Clemente, Anna Nappi, Nicoletta Zanaletti, Alfonso De Stefano, Antonio Avallone, Vincenza Granata, Carmen Notariello, Amalia Luce, Angela Lombardi, Carmine Picone, Antonella Petrillo, Francesco Perri, Fabiana Tatangelo, Annabella Di Mauro, Vittorio Albino, Francesco Izzo, Daniela Rega, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gianfranco De Feo, Paola Del Prete, Gerardo Botti, Paolo Delrio, Michele Caraglia, Guglielmo Nasti
Summary: The study aims to compare the efficacy of second-line treatments with FOLFIRI/bevacizumab beyond progression versus FOLFIRI/aflibercept in mRAS mCRC patients, and to identify angiogenic factors' patterns that could assist oncologists in applying anti-angiogenic strategies more effectively.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Ophthalmology
Ali Salimi, Natalia Vila, Milad Modabber, Michael Kapusta
Summary: This study investigated the anatomical and functional changes associated with Aflibercept treatment in Bevacizumab nonresponders with chronic DME in a Canadian setting. The results highlighted the efficacy of Aflibercept as an alternative therapeutic option for DME recalcitrant to Bevacizumab, with potential additional benefit to those with worse vision, greater CST, and better glycemic control at baseline.
INDIAN JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Maya H. Maloney, Stephanie R. Payne, Jeph Herrin, Lindsey R. Sangaralingham, Nilay D. Shah, Andrew J. Barkmeier
Summary: This study aimed to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept in real-world clinical practice. The results showed no significant differences in the risk of acute myocardial infarction, acute cerebrovascular disease, major bleeding, or all-cause hospitalization after treatment initiation with any of the three anti-VEGF agents.
Article
Ophthalmology
Yngvil Solheim Husum, Morten Carstens Moe, Ragnheidur Bragadottir, Oystein Kalsnes Jorstad
Summary: The study compared outcomes of switching treatment-resistant nAMD eyes to aflibercept with continuing bevacizumab therapy. Results suggest that switching to aflibercept may lead to modest visual benefit compared with continuing bevacizumab therapy.
ACTA OPHTHALMOLOGICA
(2021)
Article
Multidisciplinary Sciences
Takao Hirano, Yuichi Toriyama, Yoshihiro Takamura, Masahiko Sugimoto, Taiji Nagaoka, Yoshimi Sugiura, Fumiki Okamoto, Michiyuki Saito, Kousuke Noda, Shigeo Yoshida, Akihiro Ishibazawa, Osamu Sawada, Toshinori Murata
Summary: This study demonstrated that a 2-year treat-and-extend aflibercept regimen, combined with adjunct focal/grid laser, could effectively improve BCVA and CST in patients with diabetic macula edema.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
M. Jose Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna, M. Teresa Cano, Auxiliadora Gomez-Espana, Juan R. De la Haba-Rodriguez, Antonio Rodriguez-Ariza, Enrique Aranda
Summary: This study aimed to evaluate the potential value of circulating plasma biomarkers in patients with metastatic colorectal cancer (mCRC) prior to first-line treatment. The findings indicated that high VEGF-A and low ACE plasma levels were associated with poor overall survival (OS) after treatment. Additionally, a simple scoring system combining these biomarkers efficiently stratified patients into high- or low-risk groups, aiding in the selection of patients for anti-angiogenic therapy.
Article
Pharmacology & Pharmacy
Raquel Claramunt Garcia, Carmen Lucia Munoz Cid, Andres Sanchez Ruiz, Juan Francisco Marin Pozo
Summary: The study evaluated and compared the efficacy and safety of bevacizumab and aflibercept in second-line treatment for metastatic colorectal cancer in real-life clinical practice. Although no statistically significant differences were found in treatment time or progression-free survival, bevacizumab showed better results in overall survival and toxicity profile compared to aflibercept.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Andreas Stahl, Emine A. Sukgen, Wei-Chi Wu, Domenico Lepore, Hidehiko Nakanishi, Jan Mazela, Darius M. Moshfeghi, Robert Vitti, Aditya Athanikar, Karen Chu, Pablo Iveli, Fei Zhao, Thomas Schmelter, Sergio Leal, Evra Kofuncu, Noriyuki Azuma
Summary: In infants with ROP, intravitreal aflibercept did not meet the criteria for noninferiority compared to laser photocoagulation in terms of treatment success at week 24. Rescue treatment was less required in the intravitreal aflibercept group, but the serious adverse event rates were higher in the laser photocoagulation group. Further data would be needed for more definitive conclusions on the comparative effects of these treatments.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Multidisciplinary Sciences
Yun-I. Chou, Hao-Yun Chang, Meng-Yin Lin, Ching-Han Tseng, Tsung-Jen Wang, I-Chan Lin
Summary: Intravitreal ranibizumab was associated with a lower risk of arterial thromboembolic events compared to intravitreal aflibercept in the treatment of retinal neovascular diseases. Patients with coronary artery disease and a history of acute myocardial infarction or ischemic stroke within 6 months had a higher risk of arterial thromboembolic events.
SCIENTIFIC REPORTS
(2023)